The FDA today approved Ivax Pharmaceuticals’ esomeprazole magnesium delayed-release capsules, the first generic version of AstraZeneca’s proton pump inhibitor Nexium, for the treatment of gastroesophageal reflux disease in patients aged >1 year.
After ringing in the New Year, Americans from all walks of life have started dieting. For the 10% to 20% of Americans who experience gastric reflux, such weight loss may be the key to reducing associated symptoms.
A recent review of inappropriate prescribing among hospitalized older adults revealed that proton pump inhibitors follow only opiates and benzodiazepines as the most frequently misprescribed medications.
A new Mayo Clinic study published in Microbiome shows that patients with acid reflux who regularly receive proton pump inhibitors have less diverse gut bacteria, which heightens their risk for bone fractures, vitamin deficiencies, and infections such as Clostridium difficile and pneumonia.